Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cheap pill fix stiff arteries in insulin resistance?

NCT ID NCT03837626

Disease control Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether amiloride, a drug that blocks sodium channels, can improve artery stiffness and blood vessel function in people who are overweight and insulin resistant. 137 men and women (pre- and postmenopausal) took either amiloride or a placebo daily for 6 months. The main goal was to see if the drug could reduce a key measure of arterial stiffness, which is a risk factor for heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amiloride (a pill that blocks sodium channels in cells)
What this could lead to
If successful, this could point toward a simple, low-cost way to reduce artery stiffness and heart disease risk in people with insulin resistance.
What could go wrong
This is a small, completed trial. The drug may not show clear benefits, or results may not apply to all groups. Amiloride can affect kidney function and electrolyte balance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

137 people

The number who actually took part.

Started

Jul 2019

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 30 to 70 years of age at randomization * Body mass index (BMI) 25.1-50 kg/m2 or waist circumference \> 88 cm (\> 35 in) in women and \>102 cm (\>40 in) in men. 3, 4 * One other characteristic of metabolic syndrome (elevated triglycerides ≥150 mg/dl; HDL cholesterol \<40 mg/dl in men and \<50 mg/dl in women; blood pressure ≥130/85 mm Hg or treatment for hypertension; impaired fasting glucose (≥100 mg/dl)) or fasting insulin level \>10 mU/L (correlates with insulin resistance). Exclusion Criteria: 1. History of type 1 or type 2 diabetes 2. Known cardiovascular events within the last 12 months (stroke, acute coronary event, revascularization, heart failure hospitalization). 3. History of uncontrolled thyroid disease, chronic liver disease (cirrhosis) or GFR \<50 ml/min. 4. Use of potassium sparing medications (angiotensin II receptor blockers, angiotensin converting enzymes inhibitors or mineralocorticoid receptor blockers) or use of potassium supplements. 5. Active cancer (This criterion does not apply to those subjects with basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) 6. Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women) 7. Current tobacco use 8. Non controlled hypertension 9. Participation in regular exercise \> 3 days/wk per week at a moderate or vigorous intensity 10. Pregnancy or lactation in women (or women not using contraceptives) 11. Women who plan to become pregnant during the duration of the trial 12. Chronic use of NSAIDs 13. Potassium level \> 5.0 mqE/L at time of screening 14. Blood pressure at screening \<110/70

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Overweight and obesity

Contacts and locations

Locations

  • University of Missouri Hospital and Clinics

    Columbia, Missouri, 65201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.